A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma:: A gynecologic oncology group study
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma:: A gynecologic oncology group study
复制标题
DOI：
10.1006/gyno.2001.6182
复制
发表时间：
2001-06-01
影响因子：
4.7
通讯作者：
Nuñez, ER
中科院分区：
文献类型：
--
作者：
Hoffman, MA;Blessing, JA;Nuñez, ER
目标.评价CI-958对铂类敏感性卵巢癌复发患者的抗肿瘤疗效，并确定CI-958在这些患者中的毒性性质和程度。患者接受CI-958 560 mg/m2静脉注射，每3周1次，每1至2个周期进行肿瘤测量。23例患者中，1例完全缓解，10例缓解时间较短，病情稳定。CI-958在测试的剂量和时间表下在复发性铂敏感性卵巢癌中具有最小活性。(C)北京：科学出版社.
Objectives. To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients.Methods. Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles.Results. Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations.Conclusions. CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested. (C) 2001 Academic Press.